alpharadin

This page shows the latest alpharadin news and features for those working in and with pharma, biotech and healthcare.

FDA clears Bayer/ Algeta's prostate cancer radiotherapy

Analysts have predicted that Xofigo (formerly known as Alpharadin) could achieve sales of $650m within three years of launch and more than $1bn a year at its peak if follow-up

Latest news

Bayer pins hopes on five potential blockbusters

Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of 5.5bn by 2015. ... The German company's expectations are high for it yet to be approved riociguat and alpharadin (radium-223 chloride), as well as the recently launched
FDA fast-tracks Bayer's prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin. Bayer said yesterday the US FDA had granted fast-track status to its radiotherapeutic drug for castration-resistant prostate cancer (CRPC), raising ... The FDA granted priority review
Bayer points to four blockbusters in portfolio

Alpharadin is in phase III testing for bone metastases in patients with castration-resistant prostate cancer and should be filed for approval in the US and Europe in mid-2012.
Bayer's prostate cancer drug fast-tracked

Bayer Healthcare has said its investigational prostate cancer treatment Alpharadin has been fast-tracked for approval by the US Food and Drug Administration (FDA). ... Bayer holds the global rights to develop and commercialise Alpharadin. However, in the

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest appointments

Bayer’s former oncology head Robert Rosen joins AP Pharma

Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.
Former Bayer oncology head Robert Rosen joins AP Pharma's board

He was also involved in pre-market activities for regorafenib in the treatment of patients with gastrointestinal stromal tumours and colon cancer, as well as alpharadin for prostate cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Client Services Director – Medical Education Agency – North West...: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Senior Account Director development role to Business Director, H...: Excellent package

Account Director – Health Policy – Global Agency: Salary TBC

Associate Director: £75, 000-90, 000

Account Manager / Account Director: Competative

Senior Account Manager: Competitive Salary Offered

Global Business Development Director – Health Education: excellent commission

Account Manager / Senior Account Manager: 35, 000-40, 000

Business Director: Competitive Salary Offered

Account Director: Competitive Salary Offered

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Director, Medical Education: Salary TBC

Medical Writer: Salary TBC

Senior Medical Writer: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up: As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...